Applicant: John Oldfield et al. Serial No.: To Be Assigned

Filed: Herewith Page: 3 of 9

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of formula (I):

wherein

A is absent or is $(CH_2)_2$;

 R^{1} is C_{1-8} alkyl, $C(O)NR^{10}R^{11}$, $C(O)_{2}R^{12}$, $NR^{13}C(O)R^{14}$, $NR^{15}C(O)NR^{16}R^{17}$, $NR^{18}C(O)_{2}R^{19}$, heterocyclyl, aryl or heteroaryl;

 R^{10} , R^{13} , R^{15} , R^{16} and R^{18} are hydrogen or C_{1-6} alkyl;

 R^{11} , R^{12} , R^{14} , R^{17} and R^{19} are C_{1-8} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{3-6} cycloalkyl (optionally substituted by halo), C_{5-6} cycloalkenyl, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), heteroaryl, aryl, heteroaryloxy or aryloxy), aryl, heteroaryl, C_{3-7} cycloalkyl (optionally substituted by halo or C_{1-4} alkyl), C_{4-7} cycloalkyl fused to a phenyl ring, C_{5-7} cycloalkenyl, or, heterocyclyl (itself optionally substituted by oxo, $C(O)(C_{1-6}$ alkyl), $S(O)_k(C_{1-6}$ alkyl), halo or C_{1-4} alkyl); or R^{11} , R^{12} , R^{14} and R^{17} can also be hydrogen;

or R^{10} and R^{11} , and/or R^{16} and R^{17} may join to form a 4-, 5- or 6-membered ring which optionally includes a nitrogen, oxygen or sulphur atom, said ring being optionally substituted by C_{1-6} alkyl, $S(O)_1(C_{1-6}$ alkyl) or $C(O)(C_{1-6}$ alkyl);

 R^2 is C_{1-6} alkyl, phenyl, heteroaryl or C_{3-7} cycloalkyl;

 R^3 is H or C_{1-4} alkyl;

R⁴ is aryl or heteroaryl;

R⁵ is H or alkyl;

X is CH_2 , $(CH_2)_2$, CH=CH, OCH_2 or $S(O)_nCH_2$;

n is 0, 1 or 2;

Applicant: John Oldfield et al. Serial No.: To Be Assigned

Filed: Herewith Page: 4 of 9

unless specified otherwise aryl, phenyl and heteroaryl moieties are independently optionally substituted by one or more of halo, cyano, nitro, hydroxy, $OC(O)NR^{20}R^{21}$, $NR^{22}R^{23}$, $NR^{24}C(O)R^{25}$, $NR^{26}C(O)NR^{27}R^{28}$, $S(O)_2NR^{29}R^{30}$, $NR^{31}S(O)_2R^{32}$, $C(O)NR^{33}R^{34}$, CO_2R^{36} , $NR^{37}CO_2R^{38}$, $S(O)_qR^{39}$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-10} cycloalkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy(C_{1-6})alkyl, C_{1-6} alkoxy, phenyl, phenyl(C_{1-4})alkyl, phenoxy, phenylthio, phenylS(O), phenylS(O)₂, phenyl(C_{1-4})alkoxy, heteroaryl, heteroaryl(C_{1-4})alkyl, heteroaryloxy or heteroaryl(C_{1-4})alkoxy; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, $S(C_{1-4}$ alkyl), $S(O)(C_{1-4}$ alkyl), $S(O)_2(C_{1-4}$ alkyl), $S(O)_2NH_2$, $S(O)_2NH(C_{1-4}$ alkyl), $S(O)_2N(C_{1-4}$ alkyl)₂, cyano, C_{1-4} alkyl, C_{1-4} alkoxy, $C(O)NH_2$, $C(O)NH(C_{1-4}$ alkyl), $C(O)N(C_{1-4}$ alkyl)₂, CO_2H , $CO_2(C_{1-4}$ alkyl), $C(O)(C_{1-4}$ alkyl),

unless otherwise stated heterocyclyl is optionally substituted by C₁₋₆ alkyl [optionally substituted by phenyl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)} or heteroaryl {which itself optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}], phenyl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, OCF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}, heteroaryl {optionally substituted by halo, C₁₋₄ alkyl, C₁₋₄ alkoxy, cyano, nitro, CF₃, (C₁₋₄ alkyl)C(O)NH, S(O)₂NH₂, C₁₋₄ alkylthio, S(O)(C₁₋₄ alkyl) or S(O)₂(C₁₋₄ alkyl)}, S(O)₂NR⁴⁰R⁴¹, C(O)R⁴², C(O)₂(C₁₋₆ alkyl) (such as text butoxycarbonyl), C(O)₂(phenyl(C₁₋₂ alkyl)) (such as benzyloxycarbonyl), C(O)NHR⁴³, S(O)₂R⁴⁴, NHS(O)₂NHR⁴⁵, NHC(O)R⁴⁶, NHC(O)NHR⁴⁷ or NHS(O)₂R⁴⁸, provided none of these last four substituents is linked to a ring nitrogen;

k, l, [[p]] and q are, independently, 0, 1 or 2;

 R^{20} , R^{22} , R^{24} , R^{26} , R^{27} , R^{29} , R^{31} , R^{33} , R^{37} and R^{40} are, independently, hydrogen or C_{1-6} alkyl;

 R^{21} , R^{23} , R^{25} , R^{28} , R^{30} , R^{32} , R^{34} , R^{36} , R^{38} , R^{39} , R^{41} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} , R^{47} and R^{48} are, independently, C_{1-6} alkyl (optionally substituted by halo, hydroxy, C_{1-6} alkoxy, C_{1-6} haloalkoxy,

Applicant: John Oldfield et al.
Serial No.: To Be Assigned
Filed: Herewith

Filed: Herewit Page: 5 of 9

C₃₋₆ cycloalkyl, C₅₋₆ cycloalkenyl, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), heteroaryl, phenyl, heteroaryloxy or phenyloxy), C₃₋₇ cycloalkyl, phenyl or heteroaryl; wherein any of the immediately foregoing phenyl and heteroaryl moieties are optionally substituted with halo, hydroxy, nitro, S(C₁₋₄ alkyl), S(O)(C₁₋₄ alkyl), S(O)₂(C₁₋₄ alkyl), S(O)₂NH₂, S(O)₂NH(C₁₋₄ alkyl), S(O)₂N(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)NH(C₁₋₄ alkyl), C(O)C₁₋₄ alkyl), C(O)C₁₋₄ alkyl), NHS(O)₂(C₁₋₄ alkyl), C(O)(C₁₋₄ alkyl), CF₃ or OCF₃; and

 R^{21} , R^{23} , R^{25} , R^{28} , R^{30} , R^{34} , [[R^{35} ,]] R^{36} , R^{41} , R^{42} , R^{43} , R^{44} , R^{45} , R^{46} and R^{47} may additionally be hydrogen;

or a pharmaceutically acceptable salt thereof or a solvate thereof.

- 2. (Original) A compound as claimed in claim 1 wherein A is absent.
- 3. (Currently Amended) A compound as claimed in claim 1, [[or 2]] wherein \mathbb{R}^1 is piperidinyl or piperazinyl substituted by $S(O)_2C_{1-4}$ alkyl, $S(O)_2C_{1-4}$ haloalkyl or C(O)NH-phenyl.
- 4. (Currently Amended) A compound as claimed in claim 1, [[or 2]] wherein R^1 is phenyl substituted by $S(O)_2C_{1-4}$ alkyl.
- 5. (Currently Amended) A compound as claimed in claim 1, [[2 or 3]] wherein R² is phenyl optionally substituted by 0, 1 or 2 fluorines.
- 6. (Currently Amended) A compound as claimed in claim 1, 2, 3, 4 or 5 wherein R³ is hydrogen.
- 7. (Currently Amended) A compound as claimed in any one of the preceding claims claim 1, wherein R^4 is phenyl or benzyl, either of which is optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, $S(O)_z(C_{1-4}$ alkyl), nitro, cyano or CF_3 ; wherein z is 0, 1 or 2.

Applicant: John Oldfield et al.
Serial No.: To Be Assigned
Filed: Herewith

Page: 6 of 9

8. (Currently Amended) A compound as claimed in any one of the preceding claims claim 1, wherein R⁵ is hydrogen.

- 9. (Currently Amended) A compound as claimed in any one of the preceding claims claim 1, wherein X is CH₂ or CH=CH.
- 10. (Currently Amended) A <u>process for preparing a</u> compound of formula (I) as claimed in claim 1 can be prepared by comprising:
- a. for a compound of the invention wherein R¹ is an N-linked optionally substituted heterocycle, reacting a compound of formula (II):

wherein R², R³, R⁴, R⁵, A and X are as defined in claim 1, with a compound R¹H (wherein the H is on a heterocycle ring nitrogen atom) wherein R¹ is as defined in claim 1, in the presence of a suitable base, in a suitable solvent;

b. for a compound of the invention wherein R³ is hydrogen, coupling a compound of formula (III):

$$\begin{array}{c|c} HN & O \\ \hline A & X & N-R^4 \\ \hline R^5 & \end{array}$$
 (III)

wherein R^4 , R^5 , A and X are as defined in claim 1, with a compound of formula (IV):

$$\mathbb{R}^2$$
 \mathbb{N} \mathbb{N} \mathbb{N} \mathbb{N}

wherein R¹ and R² are as defined in claim 1, in the presence of NaBH(OAc)₃ (wherein Ac is C(O)CH₃) in a suitable solvent at room temperature;

Applicant: John Oldfield et al.
Serial No.: To Be Assigned
Filed: Herewith

Filed : Herewith Page : 7 of 9

c. activating the acid group of a compound of formula (V)

$$R^1$$
 R^2
 R^3
 R^3
 R^3

wherein X, A, R^1 , R^2 and R^3 are as defined in claim 1, and coupling the product so formed with an amine R^4R^5NH (wherein R^4 and R^5 are as defined in claim 1).

- 11. (Original) A pharmaceutical composition which comprises a compound as claimed in claim1, or a pharmaceutically acceptable salt thereof or solvate thereof, and a pharmaceutically acceptable adjuvant, diluent or carrier.
 - 12. (Cancelled)
 - 13. (Cancelled)
- 14. (Original) A method of treating a CCR5 mediated disease state comprising administering to a patient in need of such treatment an effective amount of a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof or solvate thereof.
- 15. (New) A compound as claimed in claim 2, wherein R^1 is piperidinyl or piperazinyl substituted by $S(O)_2C_{1-4}$ alkyl, $S(O)_2C_{1-4}$ haloalkyl or C(O)NH-phenyl.
- 16. (New) A compound as claimed in claim 2, wherein R^1 is phenyl substituted by $S(O)_2C_{1.4}$ alkyl.
- 17. (New) A compound as claimed in claim 2, wherein \mathbb{R}^2 is phenyl optionally substituted by 0, 1 or 2 fluorines.

Applicant: John Oldfield et al. Attorney's Docket No.: 06275-457US1 / 100888-1P US

Serial No.: To Be Assigned

Filed : Herewith Page : 8 of 9

18. (New) A compound as claimed in claim 2, wherein R³ is hydrogen.

19. (New) A compound as claimed in claim 2, wherein R^4 is phenyl or benzyl, either of which is optionally substituted by halo, C_{1-4} alkyl, C_{1-4} alkoxy, $S(O)_z(C_{1-4}$ alkyl), nitro, cyano or CF_3 ; wherein z is 0, 1 or 2.

- 20. (New) A compound as claimed in claim 2, wherein R⁵ is hydrogen.
- 21. (New) A compound as claimed in claim 2, wherein X is CH₂ or CH=CH.